{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:22Z","timestamp":1790409262167,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:02:44Z","timestamp":1772856164000},"page":"e699-e714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody\u2013Drug Conjugates for the Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0945-0144","authenticated-orcid":false,"given":"Lorenzo","family":"Cani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha S.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0001","first-page":"3","article-title":"Epidemiology, staging, and management of Multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci"},{"issue":"3","key":"10.1016\/j.clml.2026.03.003_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.03.003_bib0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14737140.2024.2344647","article-title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma","volume":"24","author":"Tacchetti","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"S1","key":"10.1016\/j.clml.2026.03.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.clml.2026.03.003_bib0005","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/cancers16132337","article-title":"Bispecific antibodies for the management of relapsed\/refractory multiple myeloma","volume":"16","author":"Tacchetti","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.clml.2026.03.003_bib0006","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2026.03.003_bib0007","unstructured":"Regeneron Pharmaceuticals, Inc. Linvoseltamab receives EMA filing acceptance for treatment of relapsed\/refractory multiple myeloma. February 2, 2024. Available at: http:\/\/tinyurl.com\/4k32t22e. Accessed: February 2, 2024"},{"key":"10.1016\/j.clml.2026.03.003_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/BLCTT.S490021","article-title":"The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: a comprehensive review","volume":"14","author":"Almodovar Diaz","year":"2024","journal-title":"Blood Lymphat Cancer Targets Ther"},{"issue":"2","key":"10.1016\/j.clml.2026.03.003_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.03.003_bib0010","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2026.03.003_bib0011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.clml.2026.03.003_bib0012","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in Multiple Myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2026.03.003_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.03.003_bib0015","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.clml.2026.03.003_bib0016","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2026.03.003_bib0017","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.03.003_bib0018","doi-asserted-by":"crossref","first-page":"e799","DOI":"10.1016\/S2352-3026(22)00322-2","article-title":"Iberdomide with dexamethasone: a new backbone for myeloma treatment?","volume":"9","author":"Rodriguez-Otero","year":"2022","journal-title":"Lancet Haematol"},{"issue":"22","key":"10.1016\/j.clml.2026.03.003_bib0019","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.03.003_bib0020","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2026.03.003_bib0021","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0022","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood-2025-1034","article-title":"Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality","volume":"146","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2026.03.003_bib0023","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0024","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2026.03.003_bib0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013targeted chimeric antigen receptor T-cell therapy for Multiple myeloma: an updated analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0026","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.003_bib0027","unstructured":"ClinicalTrials.gov. Study of BMS-986393 a GPRC5D-directed CAR T cell therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL). 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06297226. Accessed: January 30, 2026."},{"key":"10.1016\/j.clml.2026.03.003_bib0028","unstructured":"ClinicalTrials.gov. A study to compare the efficacy and safety of BMS-986393 versus standard regimens in adult participants with relapsed or refractory and lenalidomide-refractory multiple myeloma (QUINTESSENTIAL-2). 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06615479. Accessed: January 30, 2026."},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0029","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1200\/JCO.2024.42.16_suppl.7511","article-title":"OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed\/refractory multiple myeloma: long term follow-up results of phase 1 study (POLARIS)","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0030","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.03.003_bib0031","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0032","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0033","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.03.003_bib0034","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clml.2024.05.002","article-title":"Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians","volume":"24","author":"Lupia","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2026.03.003_bib0035","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.clml.2026.03.003_bib0036","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2025029360","article-title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","volume":"146","author":"Chari","year":"2025","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0037","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.003_bib0038","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0039","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual targeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2026","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0040","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results","volume":"43","author":"Van De Donk","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0041","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2024-208189","article-title":"First results of a phase 1, First-in-Human, dose escalation study of ISB 2001, a BCMAxCD38xCD3 targeting trispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Quach","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.03.003_bib0042","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0043","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.03.003_bib0044","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2026.03.003_bib0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/2643-3230.BCD-24-0354","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US Myeloma Immunotherapy Consortium","volume":"6","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0046","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","article-title":"Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM","volume":"14","author":"Malard","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2026.03.003_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70114","article-title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"HemaSphere"},{"issue":"17","key":"10.1016\/j.clml.2026.03.003_bib0048","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0049","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2025-2811","article-title":"Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in relapsed\/refractory multiple myeloma","volume":"146","author":"Scott","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.03.003_bib0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.03.003_bib0051","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","article-title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","volume":"26","author":"Hungria","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.03.003_bib0052","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.003_bib0053","unstructured":"FDA. FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma. 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma. Accessed: January 30, 2026."},{"issue":"9","key":"10.1016\/j.clml.2026.03.003_bib0054","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.03.003_bib0055","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2026.03.003_bib0056","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class\u2013exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.03.003_bib0057","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.003_bib0059","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.03.003_bib0060","series-title":"News release","year":"2024"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0061","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0062","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2024-200829","article-title":"Idecabtagene vicleucel (Ide-cel) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with an inadequate response to front-line autologous stem cell transplantation (ASCT): karMMa-2 cohort 2c extended follow-up","volume":"144","author":"Paul","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.03.003_bib0063","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0064","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2024.42.16_suppl.7505","article-title":"Efficacy and safety of ciltacabtagene autoleucel \u00b1 lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D","volume":"42","author":"Arnulf","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.003_bib0065","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","author":"Costa","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.03.003_bib0066","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2026.03.003_bib0067","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.03.003_bib0068","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.clml.2026.03.003_bib0069","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0070","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2024-198669","article-title":"Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: dreamm-9 updated interim analysis","volume":"144","author":"Usmani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.003_bib0071","article-title":"Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma","author":"Terpos","year":"2025","journal-title":"Blood J"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0072","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7567","article-title":"Design of the phase 3 DREAMM-10 study: belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM)","volume":"43","author":"Lonial","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.03.003_bib0073","doi-asserted-by":"crossref","unstructured":"Nooka AK, Joseph N, Parikh R, et al. Maintenance therapy with belantamab, pomalidomide and dexamethasone in high-risk myeloma patients: a phase 2 study with a safety run-in \u2013 interim analysis. Presented at: the 2025 International Myeloma Society Annual Meeting; September 17-20; Toronto, Canada. Abstract OA-66.","DOI":"10.1016\/S2152-2650(25)04009-1"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0074","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EM agine\/CARTITUDE-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0075","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"Dytfeld","year":"2021","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2026.03.003_bib0076","doi-asserted-by":"crossref","first-page":"TPS8053","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053","article-title":"KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma","volume":"39","author":"Usmani","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0077","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2024-206003","article-title":"Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","volume":"144","author":"Raab","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0078","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","volume":"144","author":"Zamagni","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0079","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0080","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2025.43.16_suppl.7504","article-title":"Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: initial results from MagnetisMM-6 part 1","volume":"43","author":"Quach","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0081","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2025-697","article-title":"Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: initial results from the window of opportunity phase 1\/2 LINKER-MM4 trial","volume":"146","author":"Orlowski","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.003_bib0082","unstructured":"ClinicalTrials.Gov. A study to learn how safe and how well linvoseltamab works compared to standard treatment in adult patients with multiple myeloma who are not eligible for transplant. NCT06932562. 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06932562. Accessed: February 3, 2026."},{"issue":"3","key":"10.1016\/j.clml.2026.03.003_bib0083","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0084","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0085","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.1182\/blood-2024-210976","article-title":"Real-world safety and efficacy of talquetamab for patients with heavily pretreated relapsed-refractory multiple myeloma","volume":"144","author":"Shaikh","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.03.003_bib0086","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288187","article-title":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","author":"Cani","year":"2025","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2026.03.003_bib0087","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"13","key":"10.1016\/j.clml.2026.03.003_bib0088","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0089","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1182\/blood-2025-5814","article-title":"Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma","volume":"146","author":"Razzo","year":"2025","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0090","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","article-title":"A novel, immunotherapy-based approach for the treatment of relapsed\/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody)","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2026.03.003_bib0091","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti\u2013G protein\u2013coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0092","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (cohort A) and with early relapse after first line treatment (cohort B)","volume":"142","author":"Hillengass","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.003_bib0093","doi-asserted-by":"crossref","first-page":"TPS8067","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067","article-title":"MajesTEC-9: a randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Touzeau","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0094","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1182\/blood-2024-207377","article-title":"MagnetisMM-32: evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior Anti-CD38-directed therapy","volume":"144","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.clml.2026.03.003_bib0095","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000975296.46536.6a","article-title":"PB2133: trial in progress: linker-Mm3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPD) in relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Weisel","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0096","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: phase 3 trial of talquetamab + daratumumab \u00b1 pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.03.003_bib0097","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2024-199773","article-title":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: safety and efficacy results from the phase 1b monumental-2 study","volume":"144","author":"Nooka","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:39:11Z","timestamp":1778067551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000674"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody\u2013Drug Conjugates for the Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}